Solicitor General sides with reps in GSK overtime case

Share this article:
GSK in biggest-ever $3b marketing fraud settlement
GSK in biggest-ever $3b marketing fraud settlement

The U.S. Solicitor General has filed an amicus brief taking the side of two pharmaceutical sales reps in the overtime case that they filed against GlaxoSmithKline.

The lawsuit alleges that the company denied the sales reps overtime pay by improperly considering them as outside salesmen. The term is defined by the Department of Labor, which also has definitions that distinguish between sales and promotional work.

The Solicitor General's brief argues that the plaintiffs fall into the promotional category, because unlike salesmen, they cannot take orders, negotiate prices or determine a patient's best interest—the latter being a physician's job.

The brief concedes that the drug reps could be considered salesmen, even if only in a colloquial sense, “because they seek to persuade physicians.”

GSK has argued that the sales reps trigger sales, but the Solicitor General's brief says that the restrictions which surround a drug rep's practice make it “impossible to determine with certainty whether a PSR's promotional work induced any particular prescription.”

Novartis settled a suit similar to the GSK case in January, for $99 million, and Schering-Plough was found to owe overtime pay in August.

The Supreme Court is scheduled to hear the sales rep/GSK appeal in the session beginning on April 16.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?